Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Viking Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Viking Therapeutics, Inc.

VKTX

Viking Therapeutics, Inc.

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders. Its pipeline includes drug candidates targeting obesity, NASH, lipid disorders, and rare genetic conditions like X-linked adrenoleukodystrophy. The company focuses on innovative receptor agonists, including GLP-1/GIP dual agonists and thyroid receptor beta agonists, with a business model centered on research, clinical development, licensing, and potential commercialization.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Viking Therapeutics, Inc.

1
1
Viking Therapeutics, Inc. Viking Therapeutics Reports $158.3 Million Net Loss and Increased Operating Expenses in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Viking Therapeutics, Inc. Viking Therapeutics Reports 239.4% Increase in R&D Expenses in Latest 10-K Filing

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Viking Therapeutics, Inc. Viking Therapeutics Reports Increased Operating Expenses and Net Loss for Nine Months Ending September 30, 2025

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
Viking Therapeutics, Inc. Viking Therapeutics Reports Increased Operating Expenses and Net Loss for Six Months Ended June 30, 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
Viking Therapeutics, Inc. Viking Therapeutics Reports $45.6 Million Net Loss in Q1 2025, No Revenue Generated

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Viking Therapeutics, Inc. Viking Therapeutics Reports Increased R&D Expenses and Advances Clinical Pipeline in 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Viking Therapeutics, Inc. Viking Therapeutics Reports Financial Results for Q3 2024, Net Loss Increases Amid Increased Research and Development Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments